(+/-)-SGCBD01, [(R,S)-4-(4-氯苯基)-2,3,9-三甲基-6H-1-硫杂-5,7,8,9a-四氮杂-环戊环[e]氮杂-6-基]-乙酸叔丁酯, N-(2′,5′-二甲氧基 [1,1'-联苯 ]-4-基)-3-氟-4-吡啶甲酰胺结构式
|
常用名 | (+/-)-SGCBD01, [(R,S)-4-(4-氯苯基)-2,3,9-三甲基-6H-1-硫杂-5,7,8,9a-四氮杂-环戊环[e]氮杂-6-基]-乙酸叔丁酯, N-(2′,5′-二甲氧基 [1,1'-联苯 ]-4-基)-3-氟-4-吡啶甲酰胺 | 英文名 | (+/-)-JQ1 |
|---|---|---|---|---|
| CAS号 | 1268524-69-1 | 分子量 | 456.98800 | |
| 密度 | 1.33±0.1 g/cm3(Predicted) | 沸点 | 610.4±65.0 °C(Predicted) | |
| 分子式 | C23H25ClN4O2S | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | N/A |
|
Selective inhibition of BET bromodomains.
Nature 468(7327) , 1067-73, (2010) Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'. Potent inhibitors of histone binding modules have not yet been ... |
|
|
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Nature 510(7504) , 278-82, (2014) Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. Progression to CRPC after androgen ablation therapy is predominantly driven by deregulated androgen receptor (AR) signalling. Despite the success of rece... |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2026 ChemSrc All Rights Reserved
